Related news from |
Sat, 09 Mar 2024 04:55:49 +0000 |
Director Gregory Freitag Sells 25,000 Shares of Axogen Inc (AXGN)
Director Gregory Freitag has sold 25,000 shares of Axogen Inc (NASDAQ:AXGN) on March 7, 2024, according to a recent SEC Filing.
|
Fri, 08 Mar 2024 10:37:15 +0000 |
US$13.80 - That's What Analysts Think AxoGen, Inc. (NASDAQ:AXGN) Is Worth After These Results
There's been a notable change in appetite for AxoGen, Inc. ( NASDAQ:AXGN ) shares in the week since its full-year...
|
Wed, 06 Mar 2024 13:20:43 +0000 |
AxoGen, Inc. (NASDAQ:AXGN) Q4 2023 Earnings Call Transcript
AxoGen, Inc. (NASDAQ:AXGN) Q4 2023 Earnings Call Transcript March 5, 2024 AxoGen, Inc. beats earnings expectations. Reported EPS is $-0.06, expectations were $-0.09. AXGN isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Hello, and welcome to the AxoGen, Inc. 2023 […]
|
Wed, 06 Mar 2024 12:37:47 +0000 |
AxoGen Full Year 2023 Earnings: Beats Expectations
AxoGen ( NASDAQ:AXGN ) Full Year 2023 Results Key Financial Results Revenue: US$159.0m (up 15% from FY 2022). Net loss...
|
Wed, 06 Mar 2024 02:27:07 +0000 |
Q4 2023 AxoGen Inc Earnings Call
Q4 2023 AxoGen Inc Earnings Call
|
Tue, 05 Mar 2024 12:31:50 +0000 |
Axogen Inc (AXGN) Reports Growth in Revenue and Reduction in Net Loss for Q4 and Full-Year 2023
Company Sees Increased Sales Across Core Segments and Continues to Innovate in Nerve Repair Market
|
Tue, 05 Mar 2024 12:00:00 +0000 |
Axogen, Inc Reports 2023 Fourth Quarter and Full-Year Financial Results
ALACHUA, Fla. and TAMPA, Fla., March 05, 2024 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today reported financial results and business highlights for the fourth quarter and full-year ended December 31, 2023. Fourth Quarter 2023 Financial Results and Business Highlights Fourth quarter revenue was $42.9 million, an 18.7% increase compared to the fourth quarter of 2022.The Company estimate
|
Tue, 05 Mar 2024 09:43:00 +0000 |
Zacks.com featured highlights Protagonist Therapeutics, AxoGen, Western Digital and Phunware
Protagonist Therapeutics, AxoGen, Western Digital and Phunware have been highlighted in this Screen of The Week article.
|
Mon, 04 Mar 2024 22:20:04 +0000 |
Ekso Bionics (EKSO) Reports Q4 Loss, Tops Revenue Estimates
Ekso Bionics (EKSO) delivered earnings and revenue surprises of -100% and 0.98%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
|
Wed, 28 Feb 2024 13:50:08 +0000 |
AxoGen (AXGN) Is a Great Choice for 'Trend' Investors, Here's Why
AxoGen (AXGN) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.
|
Mon, 26 Feb 2024 14:15:12 +0000 |
AxoGen, Inc. (AXGN) Hit a 52 Week High, Can the Run Continue?
AxoGen (AXGN) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
|
Tue, 20 Feb 2024 10:06:00 +0000 |
Zacks.com featured highlights AxoGen, Western Digital and Gen Digital
AxoGen, Western Digital and Gen Digital have been highlighted in this Screen of The Week article.
|
Fri, 16 Feb 2024 11:08:00 +0000 |
3 Best Stocks to Buy for Remarkable Earnings Acceleration
Invest in stocks such as AxoGen (AXGN), Western Digital (WDC) and Gen Digital (GEN) as of now for superb earnings acceleration.
|
Tue, 13 Feb 2024 21:30:00 +0000 |
Axogen, Inc. to Report 2023 Fourth Quarter and Full-Year Financial Results on March 5, 2024
ALACHUA, Fla. and TAMPA, Fla., Feb. 13, 2024 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced that it will report 2023 fourth quarter and full-year financial results on Tuesday, March 5, 2024, before the market opens. Axogen management will host an investment-community conference call and webcast at 8 a.m. ET following the release. Investors interested in participating in the
|
Mon, 12 Feb 2024 13:50:05 +0000 |
Here's Why Momentum in AxoGen (AXGN) Should Keep going
If you are looking for stocks that are well positioned to maintain their recent uptrend, AxoGen (AXGN) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.
|
Tue, 06 Feb 2024 14:40:08 +0000 |
Is AxoGen (AXGN) Stock Outpacing Its Medical Peers This Year?
Here is how AxoGen (AXGN) and Boston Scientific (BSX) have performed compared to their sector so far this year.
|
Fri, 02 Feb 2024 21:15:00 +0000 |
Company Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
ALACHUA, Fla. and TAMPA, Fla., Feb. 02, 2024 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced making Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) in connection with the employment and appointment of John Manning to the position of Area Vice President of Sales. Mr. Manning will report to Doris Quackenbush, Vice President of Sales. In connection with the commencement o
|
Tue, 30 Jan 2024 13:43:00 +0000 |
Zacks.com featured highlights include AxoGen, Western Digital, Accolade and Credo Technology Group
AxoGen, Western Digital, Accolade and Credo Technology Group are part of the Screen of the Week article.
|
Fri, 26 Jan 2024 13:50:05 +0000 |
Here's What Could Help AxoGen (AXGN) Maintain Its Recent Price Strength
If you are looking for stocks that are well positioned to maintain their recent uptrend, AxoGen (AXGN) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.
|
Thu, 18 Jan 2024 22:00:00 +0000 |
Axogen, Inc. Announces Positive Topline Results from REPOSE, a Prospective, Randomized Clinical Trial of Axoguard Nerve Cap
REPOSE® met its primary endpoint of non-inferiority between the pain visual analog scale outcomes for neurectomy with Axoguard Nerve Cap® vs. standard-of-care neurectomy at Month 12. Axoguard Nerve Cap demonstrated statistical superiority vs. standard-of-care neurectomy in the reduction of total pain reported by participants over the course of follow-up. ALACHUA, Fla. and TAMPA, Fla., Jan. 18, 2024 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innov
|